This may be explained by the fact that Gal-9 released from tumor cells suppresses anti-tumor immunity by interacting with various surface receptors including TIM-3, PD-1, VISTA, CD40, CD44 and DR3 [7–12] in T lymphocytes, leading to T cell exhaustions and immune tolerance. This evidence concerns the gene TNFRSF25 and neoplasm.